RXi Pharmaceuticals (RXII) Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board
7/13/2012 10:25:06 AM
WESTBOROUGH, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced the appointment of Dr. Jeannette Graf and Dr. Leroy Young to its Scientific Advisory Board. The addition of these two highly esteemed clinicians provides RXi with invaluable experience and clinical research expertise that are key to the ongoing development of RXI-109. RXI-109 is a self-delivering RNAi compound (sd-rxRNA®) developed by RXi for the reduction of dermal scarring in planned surgeries. RXI-109 entered into a Phase 1 clinical study in June 2012.
comments powered by